HCT in CR1 Beneficial to Outcomes for Older AML Patients

This single-center study examined outcomes of 242 consecutive adults transplanted for AML. Median age was 48 years (18-71), and outcomes were compared among four patient groups defined by age (<60 or ≥60 years) and remission status (CR1 or CR2). At a median follow-up of 65 months, three-year survival of CR1/<60, CR2/<60, CR1≥60, and CR2/≥60 were 57%, 43%, 39%, and 16%, respectively (p=0.003). In a multivariate analysis comparing CR2/≥60 with CR1/≥60, hazard ratios of non-relapse mortality and survival were 2.08 (p=0.06) and 1.52 (p=0.23), respectively. The researchers conclude that if a transplant is indicated, early referral to prepare for transplant in CR1 is recommended in patients ≥60 years with AML.

Michelis FV, et al. Biol Blood Marrow Transplant